Mitogen-activated protein kinase signaling pathway in oral cancer (Review)
- Authors:
- Qian Peng
- Zhiyuan Deng
- Hao Pan
- Liqun Gu
- Ousheng Liu
- Zhangui Tang
-
Affiliations: Xiangya Stomatological Hospital, Central South University, Changsha, Hunan 410008, P.R. China - Published online on: November 24, 2017 https://doi.org/10.3892/ol.2017.7491
- Pages: 1379-1388
This article is mentioned in:
Abstract
 |
|
Grsic K, Opacic IL, Sitic S, Milkovic Perisa M, Suton P and Sarcevic B: The prognostic significance of estrogen receptor β in head and neck squamous cell carcinoma. Oncol Lett. 12:3861–3865. 2016.PubMed/NCBI | |
|
Peng Q, Wang Y, Quan H, Li Y and Tang Z: Oral verrucous carcinoma: From multifactorial etiology to diverse treatment regimens (Review). Int J Oncol. 49:59–73. 2016.PubMed/NCBI | |
|
Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P and Eccles SA: Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev. 24:47–69. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Smolensky D, Rathore K, Bourn J and Cekanova M: Inhibition of the PI3K/AKT pathway sensitizes oral squamous cell carcinoma cells to anthracycline-based chemotherapy in vitro. J Cell Biochem. 118:2615–2624. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pramanik KK, Singh AK, Alam M, Kashyap T, Mishra P, Panda AK, Dey RK, Rana A, Nagini S and Mishra R: Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer. Tumour Biol. 37:15253–15264. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis. J Recept Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chiba T, Soeno Y, Shirako Y, Sudo H, Yagishita H, Taya Y, Kawashiri S, Okada Y and Imai K: MALT1 Inhibition of oral carcinoma cell invasion and ERK/MAPK activation. J Dent Res. 95:446–452. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Affolter A, Muller MF, Sommer K, Stenzinger A, Zaoui K, Lorenz K, Wolf T, Sharma S, Wolf J, Perner S, et al: Targeting irradiation-induced mitogen-activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. Head Neck. 38 Suppl 1:E2049–E2061. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim GT, Lee SH and Kim YM: Torilis japonica extract-generated intracellular ROS induces apoptosis by reducing the mitochondrial membrane potential via regulation of the AMPK-p38 MAPK signaling pathway in HCT116 colon cancer. Int J Oncol. 49:1088–1098. 2016.PubMed/NCBI | |
|
Song X, Wei Z and Shaikh ZA: Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells. Toxicol Appl Pharmacol. 287:26–34. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li L, Wu W and Hann S: p38α MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. J Exp Clin Cancer Res. 33:362014. View Article : Google Scholar : PubMed/NCBI | |
|
Aguzzi A, Maggioni D, Nicolini G, Tredici G, Gaini RM and Garavello W: MAP kinase modulation in squamous cell carcinoma of the oral cavity. Anticancer Res. 29:303–308. 2009.PubMed/NCBI | |
|
Burotto M, Chiou VL, Lee JM and Kohn EC: The MAPK pathway across different malignancies: A new perspective. Cancer. 120:3446–3456. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang SH, Sharrocks AD and Whitmarsh AJ: MAP kinase signaling cascades and transcriptional regulation. Gene. 513:1–13. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Krishna M and Narang H: The complexity of mitogen-activated protein kinases (MAPKs) made simple. Cell Mol Life Sci. 65:3525–3544. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Samatar AA and Poulikakos PI: Targeting RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Crane EK and Wong KK: The therapeutic promise of anti-cancer drugs against the Ras/Raf/MEK/ERK pathway. Topics Anti-Cancer Res. 2:63–94. 2013. View Article : Google Scholar | |
|
Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A and Kolch W: Raf family kinases: Old dogs have learned new tricks. Genes Cancer. 2:232–260. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ahearn IM, Haigis K, Bar-Sagi D and Philips MR: Regulating the regulator: Post-translational modification of RAS. Nat Rev Mol Cell Biol. 13:39–51. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pratilas CA and Solit DB: Targeting the mitogen-activated protein kinase pathway: Physiological feedback and drug response. Clin Cancer Res. 16:3329–3334. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wortzel I and Seger R: The ERK cascade: Distinct functions within various subcellular organelles. Genes Cancer. 2:195–209. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gough NR: Focus issue: Recruiting players for a game of ERK. Sci Signal. 4:eg92011. View Article : Google Scholar : PubMed/NCBI | |
|
Ku NO, Azhar S and Omary MB: Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization: Modulation by a keratin 1-like disease causing mutation. J Biol Chem. 277:10775–10782. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Gkouveris I, Nikitakis N, Karanikou M, Rassidakis G and Sklavounou A: JNK1/2 expression and modulation of STAT3 signaling in oral cancer. Oncol Lett. 12:699–706. 2016.PubMed/NCBI | |
|
Park MK, Lee HJ, Shin J, Noh M, Kim SY and Lee CH: Novel participation of transglutaminase-2 through c-Jun N-terminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells. Biochim Biophys Acta. 1811:1021–1029. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mishima K, Inoue K and Hayashi Y: Overexpression of extracellular-signal regulated kinases on oral squamous cell carcinoma. Oral Oncol. 38:468–474. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Simões AE, Rodrigues CM and Borralho PM: The MEK5/ERK5 signalling pathway in cancer: A promising novel therapeutic target. Drug Discov Today. 21:1654–1663. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ and Lee JD: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature. 395:713–716. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Raviv Z, Kalie E and Seger R: MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation. J Cell Sci. 117:1773–1784. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li T, Pan YW, Wang W, Abel G, Zou J, Xu L, Storm DR and Xia Z: Targeted deletion of the ERK5 MAP kinase impairs neuronal differentiation, migration, and survival during adult neurogenesis in the olfactory bulb. PLoS One. 8:e619482013. View Article : Google Scholar : PubMed/NCBI | |
|
Koyama T, Ogawara K, Kasamatsu A, Okamoto A, Kasama H, Minakawa Y, Shimada K, Yokoe H, Shiiba M, Tanzawa H and Uzawa K: ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer. Cancer Med. 4:759–769. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shimizu T, Kasamatsu A, Yamamoto A, Koike K, Ishige S, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Uzawa K: Annexin A10 in human oral cancer: Biomarker for tumoral growth via G1/S transition by targeting MAPK signaling pathways. PLoS One. 7:e455102012. View Article : Google Scholar : PubMed/NCBI | |
|
Wakasaki T, Masuda M, Niiro H, Jabbarzadeh-Tabrizi S, Noda K, Taniyama T, Komune S and Akashi K: A Critical role of c-Cbl-Interacting protein of 85 kDa in the development and progression of head and neck squamous cell carcinomas through the Ras-ERK pathway. Neoplasia. 12:789–796. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fu X and Feng Y: QKI-5 suppresses cyclin D1 expression and proliferation of oral squamous cell carcinoma cells via MAPK signalling pathway. Int J Oral Maxillofac Surg. 44:562–567. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Williams MD: Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol. 4:62–69. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y, Zhang Y, Hua S, Fu Q, Zhao M, et al: Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 5:e11552014. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada T, Tsuda M, Ohba Y, Kawaguchi H, Totsuka Y and Shindoh M: PTHrP promotes malignancy of human oral cancer cell downstream of the EGFR signaling. Biochem Biophys Res Commun. 368:575–581. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu D, Cheng J, Sun G, Wu S, Li M, Gao Z, Zhai S, Li P, Su D and Wang X: p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma. Oncotarget. 7:36539–36550. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yang RW, Zeng YY, Wei WT, Cui YM, Sun HY, Cai YL, Nian XX, Hu YT, Quan YP, Jiang SL, et al: TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways. J Exp Clin Cancer Res. 35:1522016. View Article : Google Scholar : PubMed/NCBI | |
|
Huang RH, Quan YJ, Chen JH, Wang TF, Xu M, Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes cell migration and invasion, and inhibits apoptosis and autophagy in colorectal cancer by activating the p38 MAPK signaling pathway. Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lv D, Wu H, Xing R, Shu F, Lei B, Lei C, Zhou X, Wan B, Yang Y, Zhong L, et al: HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways. Oncotarget. 8:13586–13599. 2017.PubMed/NCBI | |
|
Chen H, Jin ZL and Xu H: MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol. Asian Pac J Trop Med. 9:49–53. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang T, Liao Y, Sun Q, Tang H, Wang G, Zhao F and Jin Y: Upregulation of matrix metalloproteinase-9 in primary cultured rat astrocytes induced by 2-chloroethanol Via MAPK signal pathways. Front Cell Neurosci. 11:2182017. View Article : Google Scholar : PubMed/NCBI | |
|
Schafer JM, Peters DE, Morley T, Liu S, Molinolo AA, Leppla SH and Bugge TH: Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin. PLoS One. 6:e205322011. View Article : Google Scholar : PubMed/NCBI | |
|
Munshi HG, Wu YI, Mukhopadhyay S, Ottaviano AJ, Sassano A, Koblinski JE, Platanias LC and Stack MS: Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem. 279:39042–39050. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
So KY, Kim SH, Jung KT, Lee HY and Oh SH: MAPK/JNK1 activation protects cells against cadmium-induced autophagic cell death via differential regulation of catalase and heme oxygenase-1 in oral cancer cells. Toxicol Appl Pharmacol. 332:81–91. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Cossa G, Gatti L, Cassinelli G, Lanzi C, Zaffaroni N and Perego P: Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des. 19:883–894. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16 Suppl 2:S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Liu J, Cui F, Xing L, Wang J, Yan X and Zhang X: ERK and p38 MAPK signaling pathways are involved in ochratoxin A-induced G2 phase arrest in human gastric epithelium cells. Toxicol Lett. 209:186–192. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ahn HJ, Kim G and Park KS: Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway. Biochem Biophys Res Commun. 437:557–564. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A and Raymond E: Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev. 32:147–162. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmeda TA, Hayslip J and Leggas M: Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leuk Res. 38:1350–1357. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JC, Chung LC, Chen YJ, Feng TH, Chen WT and Juang HH: Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells. Cancer Lett. 360:310–318. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
D'Ambrosio SM, Han C, Pan L, Kinghorn AD and Ding H: Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway. Biochem Biophys Res Commun. 409:465–469. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE and D'Silva NJ: Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem. 280:22564–22571. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tang FY, Chiang EP, Chung JG, Lee HZ and Hsu CY: S-Allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. J Nutr Biochem. 20:1013–1020. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ko CP, Lin CW, Chen MK, Yang SF, Chiou HL and Hsieh MJ: Pterostilbene induce autophagy on human oral cancer cells through modulation of Akt and mitogen-activated protein kinase pathway. Oral Oncol. 51:593–601. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kavitha K, Kowshik J, Kishore TK, Baba AB and Nagini S: Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta. 1830:4433–4444. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Han HY, Kim H, Jeong SH, Lim DS and Ryu MH: Sulfasalazine induces autophagic cell death in oral cancer cells via Akt and ERK pathways. Asian Pac J Cancer Prev. 15:6939–6944. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ and Forastiere AA: Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303. Clin Cancer Res. 20:3023–3032. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshimoto T, Takino T, Li Z, Domoto T and Sato H: Vinculin negatively regulates transcription of MT1-MMP through MEK/ERK pathway. Biochem Biophys Res Commun. 455:251–255. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen HJ, Lin CM, Lee CY, Shih NC, Amagaya S, Lin YC and Yang JS: Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling. Int J Oncol. 43:629–637. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yen CY, Liang SS, Han LY, Chou HL, Chou CK, Lin SR and Chiu CC: Cardiotoxin III inhibits proliferation and migration of oral cancer cells through MAPK and MMP signaling. Scientific World Journal. 2013:6509462013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin FY, Hsieh YH, Yang SF, Chen CT, Tang CH, Chou MY, Chuang YT, Lin CW and Chen MK: Resveratrol suppresses TPA-induced matrix metalloproteinase-9 expression through the inhibition of MAPK pathways in oral cancer cells. J Oral Pathol Med. 44:699–706. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, et al: Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14:38–47. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, et al: BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 119:548–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Das N, Majumder J and DasGupta UB: Ras gene mutations in oral cancer in eastern India. Oral Oncol. 36:76–80. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Collisson EA, De A, Suzuki H, Gambhir SS and Kolodney MS: Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res. 63:5669–5673. 2003.PubMed/NCBI | |
|
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al: Mechanism of activation of the RAF-ERK signalingpathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Antipina MN, Kiryukhin MV, Skirtach AG and Sukhorukov GB: Micropackaging via layer-by-layer assembly: Microcapsulesand microchamber arrays. Int Mater Rev. 59:224–244. 2014. View Article : Google Scholar | |
|
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY). 3:192–222. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, et al: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and JAK/STAT pathways to leukemia. Leukemia. 22:686–707. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Carlino MS, Gowrishankar K, Saunders CA, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV and Rizos H: Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther. 12:1332–1342. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart DD: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Imparato G, Urciuolo F and Netti PA: In vitro three-dimensional models in cancer research: A review. Int Mater Rev. 60:297–311. 2015. View Article : Google Scholar |
